Caricamento...

A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction

Immune dysregulation is a mechanism contributing to ineffective hematopoiesis in a subset of myelodysplastic syndrome patients. We report the first US multicenter non-randomized, phase II trial examining the efficacy of rabbit(r)-anti-thymocyte globulin using 2.5 mg/kg/day administered daily for 4 d...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Komrokji, Rami S., Mailloux, Adam W., Chen, Dung-Tsa, Sekeres, Mikkael A., Paquette, Ronald, Fulp, William J., Sugimori, Chiharu, Paleveda-Pena, Jennifer, Maciejewski, Jaroslaw P., List, Alan F., Epling-Burnette, Pearlie K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ferrata Storti Foundation 2014
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077078/
https://ncbi.nlm.nih.gov/pubmed/24488560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.083345
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !